Table 2.
Treatment responses
| ORd | OCyd | OMP | ||
|---|---|---|---|---|
| 5/14 Schedule, 150–210 mg OPZ N = 13 | 2/7 Schedule, 210 or 240 mg OPZ N = 5 | 2/7 Schedule, 210 mg OPZ N = 3 | 2/7 Schedule, 180 mg OPZ N = 7 | |
| Best overall response, n (%) | ||||
| Stringent complete response | 0 | 1 (20.0) | 0 | 0 |
| Complete response | 2 (15.4) | 0 | 0 | 1 (14.3) |
| Very good partial response | 2 (15.4) | 2 (40.0) | 1 (33.3) | 0 |
| Partial response | 4 (30.8) | 1 (20.0) | 2 (66.7) | 2 (28.6) |
| Stable disease | 1 (7.7) | 0 | 0 | 3 (42.9) |
| Not evaluable | 2 (15.4) | 0 | 0 | 0 |
| Missing or unknown | 2 (15.4) | 1 (20.0) | 0 | 1 (14.3) |
| Overall response rate, % | 61.5 | 80.0 | 100.0 | 42.9 |
OCyd oprozomib, cyclophosphamide, and dexamethasone; OMP oprozomib, melphalan, and prednisone; OPZ oprozomib; ORd oprozomib, lenalidomide, and dexamethasone